Abstract : Anti-Mi2 are dermatomyositis-specific autoantibodies (Aabs) that have been associated, in small cohorts, with a good prognosis possibly related to a lower malignancy risk. Our objective was to describe the phenotype of anti-Mi-2 dermatomyositis (DM) in a larger cohort. A national multicenter retrospective cohort study was performed including all patients with a clinical phenotype suggestive of DM (cutaneous manifestations and/or muscle involvement) and a positive anti-Mi2 Aabs. Medical records were retrospectively reviewed to assess clinical and histological features, and presence of cancer occurring ± 3 years of diagnosing myositis (CAM).
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01664160
Contributeur : Lnc - Université de Bourgogne
<>
Soumis le : jeudi 14 décembre 2017 - 15:32:01
Dernière modification le : vendredi 8 juin 2018 - 14:50:12
O. Landon-Cardinal, G. Monseau, Y. Schoindre, A. Rigolet, N. Champtiaux, et al.. Anti-Mi2 dermatomyositis revisited: pure DM phenotype with muscle fiber necrosis and high risk of malignancy. 22nd International Congress of the World Muscle Society, Oct 2017, Saint Malo, France. Neuromuscular Disorders, 27 (Suppl. 2), pp.S153 2017, 〈http://www.nmd-journal.com/article/S0960-8966(17)30791-5/fulltext〉. 〈10.1016/j.nmd.2017.06.218〉. 〈hal-01664160〉
